About
Advisor supporting the biopharmaceutical team since 2023, with 25+ years in product development and commercial leadership. He was CEO of Forma Therapeutics until its $1.1B acquisition by Novo Nordisk, and previously held senior roles at Genentech.
Colleagues at Lightstone Ventures
Brendan Kelly
Principal at Lightstone Ventures
Brendan Kelly, Ph.D.
Principal at Lightstone Ventures
Caroline Gaynor
Partner at Lightstone Ventures
Christina Isacson
Partner at Lightstone Ventures
Christina Isacson, Ph.D.
Partner at Lightstone Ventures
Doug Treco
Advisor at Lightstone Ventures
Doug Treco, Ph.D.
Advisor at Lightstone Ventures
H. Martin Seidel
Advisor at Lightstone Ventures